InsiderTrades.com logo
The only accurate crypto trading system I know …
From Weiss Ratings   |   Ad
Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.
Here's what our expert says you should buy before April 14.
Eric Dobmeier net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Eric Dobmeier Biography and Net Worth

CEO of Chinook Therapeutics
Eric is President and CEO of Chinook Therapeutics. Previously, he was President and CEO of Silverback Therapeutics, a Seattle-based biotechnology company in the immuno-oncology space. Prior to that, he spent more than 15 years at Seattle Genetics, most recently as Chief Operating Officer, where he oversaw business development, corporate communications, manufacturing, program/alliance management activities and corporate strategy initiatives. While at Seattle Genetics, Eric was also directly involved in raising more than $1.2 billion in equity capital, and led negotiation and completion of multiple corporate alliances with leading biotechnology and pharmaceutical companies. Earlier in his career, he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Eric has a J.D. from University of California, Berkeley School of Law and an undergraduate degree from Princeton University. He is also a director of Atara Biotherapeutics and Adaptive Biotechnologies.

What is Eric Dobmeier's net worth?

The estimated net worth of Eric Dobmeier is at least $12.21 million as of April 24th, 2023. Mr. Dobmeier owns 302,338 shares of Chinook Therapeutics stock worth more than $12,211,432 as of April 19th. This net worth evaluation does not reflect any other investments that Mr. Dobmeier may own. Additionally, Mr. Dobmeier receives a salary of $972,190.00 as CEO at Chinook Therapeutics. Learn More about Eric Dobmeier's net worth.

How old is Eric Dobmeier?

Mr. Dobmeier is currently 54 years old. There are 4 older executives and no younger executives at Chinook Therapeutics. Learn More on Eric Dobmeier's age.

What is Eric Dobmeier's salary?

As the CEO of Chinook Therapeutics, Inc., Mr. Dobmeier earns $972,190.00 per year. Learn More on Eric Dobmeier's salary.

How do I contact Eric Dobmeier?

The corporate mailing address for Mr. Dobmeier and other Chinook Therapeutics executives is 740 HEINZ AVENUE, BERKELEY CA, 94710. Chinook Therapeutics can also be reached via phone at (206) 485-7241 and via email at [email protected]. Learn More on Eric Dobmeier's contact information.

Has Eric Dobmeier been buying or selling shares of Chinook Therapeutics?

Eric Dobmeier has not been actively trading shares of Chinook Therapeutics within the last three months. Most recently, Eric Dobmeier sold 23,800 shares of the business's stock in a transaction on Monday, April 24th. The shares were sold at an average price of $21.58, for a transaction totalling $513,604.00. Following the completion of the sale, the chief executive officer now directly owns 302,338 shares of the company's stock, valued at $6,524,454.04. Learn More on Eric Dobmeier's trading history.

Who are Chinook Therapeutics' active insiders?

Chinook Therapeutics' insider roster includes Srinivas Akkaraju (Director), Eric Bjerkholt (CFO), Jerel Davis (Director), Eric Dobmeier (CEO), Tom Frohlich (COO), Alan Glicklich (Insider), and Andrew King (Insider). Learn More on Chinook Therapeutics' active insiders.

Are insiders buying or selling shares of Chinook Therapeutics?

In the last twelve months, insiders at the sold shares 3 times. They sold a total of 26,123 shares worth more than $586,102.54. The most recent insider tranaction occured on August, 1st when insider Andrew James King sold 1,168 shares worth more than $45,587.04. Insiders at Chinook Therapeutics own 16.8% of the company. Learn More about insider trades at Chinook Therapeutics.

Information on this page was last updated on 8/1/2023.

Eric Dobmeier Insider Trading History at Chinook Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/24/2023Sell23,800$21.58$513,604.00302,338View SEC Filing Icon  
2/10/2023Sell8,097$23.75$192,303.75301,138View SEC Filing Icon  
1/30/2023Sell25,000$24.54$613,500.00271,676View SEC Filing Icon  
12/1/2022Sell30,000$22.31$669,300.00241,676View SEC Filing Icon  
5/25/2022Buy5,000$13.03$65,150.00205,880View SEC Filing Icon  
9/20/2021Buy2,000$12.00$24,000.00View SEC Filing Icon  
8/18/2021Buy7,000$11.74$82,180.00View SEC Filing Icon  
5/14/2021Buy1,000$14.44$14,440.00View SEC Filing Icon  
12/8/2020Buy2,000$13.24$26,480.00View SEC Filing Icon  
11/23/2020Buy929$13.67$12,699.43View SEC Filing Icon  
11/19/2020Buy500$13.50$6,750.00View SEC Filing Icon  
11/10/2020Buy2,000$13.86$27,720.00View SEC Filing Icon  
See Full Table

Eric Dobmeier Buying and Selling Activity at Chinook Therapeutics

This chart shows Eric Dobmeier's buying and selling at Chinook Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Chinook Therapeutics Company Overview

Chinook Therapeutics logo
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.
Read More

Today's Range

Now: $40.39
Low: $40.39
High: $40.39

50 Day Range

MA: $39.86
Low: $38.66
High: $40.39

2 Week Range

Now: $40.39
Low: $18.34
High: $40.51

Volume

N/A

Average Volume

1,186,257 shs

Market Capitalization

$2.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34
The only accurate crypto trading system I know …
From Weiss Ratings   |   Ad
Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.
Here's what our expert says you should buy before April 14.